InspireMD, Inc. (NASDAQ:NSPR) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET

Company Participants

Chuck Padala - IR, Life Advisors
Marvin Slosman - CEO
Craig Shore - CFO
Shane Gleason - CCO

Conference Call Participants

Adam Maeder - Piper Sandler

Operator

Good day, everyone, and welcome to the InspireMD Third Quarter 2024 Earnings Call.

Currently, all participants are in a listen-only mod e. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions]. Please note, this conference is being recorded.

I will now turn the conference over to Chuck Padala with LifeSci Advisors. Thank you. You may begin.

Chuck Padala

Thank you, operator, and good morning, everyone. Thank you for joining us for the InspireMD third quarter financial results and corporate update conference call. Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer; and Craig Shore, Chief Financial Officer. Shane Gleason, Chief Commercial Officer will also be available for Q&A.

During this call, management will be making forward-looking statements, not historical facts, which are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. These forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those expressed in such forward-looking statements. For more information about these risks, please refer to the Risk Factors described in InspireMD's most recently filed periodic reports on Form 10-K and Form 10-Q or any updates in our corporate reports on Form 8-K filed with the U.S. Security and Exchange Commission and InspireMD's press release that accompanies this call, particularly the cautionary statements made in it.

This call contains time-sensitive information that is accurate only as of today, November 12, 2024, except as required by law, InspireMD disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call.

It's now my pleasure to turn the call over to Marvin Slosman, Chief Executive Officer. Marvin, please go ahead.

Marvin Slosman

Thank you, Chuck, and thanks to everyone for joining the call this morning.

I'd like to begin with a review of our very strong Q3 financial results. We reported total CGuard revenue of $1.81 million representing growth of more than 16% over the third quarter of last year. Our results were driven by sales of over 3,100 CGuard implants during the quarter, representing growth of nearly 14% over the same period last year to the benefit of thousands of patients in our end markets suffering from carotid artery disease.